Phase 1 N=27 LY2189265 and Atorvastatin Interaction Study
Healthy Volunteers
Primary: Pharmacokinetics of Atorvastatin: Maximum Plasma Concentration (Cmax) — 19.5; 5.78 nanogram per milliliter (ng/mL)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=31 A Study of the Effect of LY2189265 on Two Blood Pressure Drugs
Diabetes Mellitus, Type 2
Primary: Pharmacokinetics, Area Under the Concentration Curve (AUC) of Lisinopril — 1580; 1740; 1660; 1720 (nanograms*hours/milliliter)/milligram
Phase 1 N=22 A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants
Diabetes Mellitus, Type 2
Primary: Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) at Steady State of Ortho-Cyclen - Norelgestromin (NGMN) — 17900; 16000 picograms*hour/milliliter…
Phase 1 N=30 A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.
Diabetes Mellitus, Type II
Primary: Dose Normalized Area Under the Concentration Time Curve (AUC) of LY2189265: Subcutaneous (SC) to Intravenous (IV) — 10256; 23150 nanograms*hour/milliliter/milligram
Phase 1 N=29 A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Sitagliptin — 3210; 3240; 2970 nanograms times hour/milliliter(ng*h/mL)
Phase 1 N=28 A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants
Diabetes Mellitus, Type 2
Primary: Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of R-warfarin and S-warfarin — 19200; 18900; 33000; 32900 nanograms times hours per milliliter
Phase 1 N=16 A Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy Subjects
Diabetes Mellitus
Primary: Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) — 1900; 2180 picomole*hour per liter (pmol*hr/L)
Phase 1 N=26 A Single Dose Study of LY2189265 in Subjects With Varying Degrees of Hepatic (Liver) Impairment
Diabetes Mellitus, Type 2
Primary: Pharmacokinetics: Maximum Observed Concentration (Cmax) — 84.5; 63.0; 58.1; 61.3 nanograms/milliliter (ng/mL)
Phase 1 N=91 A Study to Compare LY2963016 and US-approved Lantus® After Single Dose Administration to Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY2963016 and US-Approved Lantus — 1720; 1900 picomoles*hour/liter (pmol*h/L)
Phase 1 N=32 Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose
Diabetes Mellitus, Type 2
Primary: Maximum Insulin Concentration (Cmax) - First Phase Response — 233; 689; 74.3; 401 picomole per liter (pmol/L) — p=<0.001
Phase 1 N=20 A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus
Diabetes Mellitus, Type 1
Primary: Pharmacodynamics: Duration of Action of LY2963016 and Lantus — 37.13; 40.00 hours (hr)
Phase 1 N=80 A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY2963016 to Lantus in Healthy Participants
Diabetes Mellitus
Primary: Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to 24 Hours [AUC(0-24)] of LY2963016 and Lantus — 1810; 1980 picomoles*hour/Liter (pmol*h/L)
Phase 1 N=24 A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants
Diabetes Mellitus, Type 2
Primary: Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Digoxin — 16.8; NA; NA; 16.1 nanograms times hours/milliliter
Phase 1 N=24 A Study of LY2963016 in Healthy Participants
Healthy Volunteers
Primary: Pharmacokinetics: Area Under the Serum LY2963016 or Lantus Concentration-Time Curve (AUC) From Zero to Infinity [AUC(0-∞)] — 2330; 4470; 2390; 4310 picomoles*hour per…
Phase 1 N=38 A Study to Evaluate the Effect of LY2189265 on the Speed at Which Food and Drink Leaves the Stomach in Patients With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Time Required for 50% of Radioactivity To Be Emptied From the Stomach by Scintigraphy — 1.44; 1.72; 1.41; 3.77 hours